What VLife Sciences Technologies Pvt. Ltd. does

VLife Sciences Technologies Pvt. Ltd. is a Pune, India-based provider of computational molecular discovery and drug design software, operating as a division of NovaLead Pharma Pvt. Ltd. since October 2013. Founded in 2003, the company builds and licenses an integrated software portfolio consisting of four core suites — VLifeMDS (flagship molecular design suite), QSARpro (quantitative structure-activity relationship analysis), BioPredicta (bioinformatics predictive analysis), and ChemXplor (cheminformatics exploration) — complemented by nine functional products covering protein modeling, molecular docking, QSAR modeling, lead optimization, and visualization. The underlying technology stack combines proprietary methods including GQSAR (Group-based QSAR), VLifeSCOPE (residue-ligand interaction modeling), kNN-MFA, and VLifeAutoQSAR for predictive modeling, virtual screening, lead optimization, scaffold hopping, and ADME/Tox prediction, supported by 300+ man-years of accumulated research experience and granted IP including a PCT patent on G-QSAR and an NCE patent on a multi-targeted pancreatic cancer compound discovered using VLife's computational platform.

The company's business model combines software licensing (Individual User and Organizational User subscriptions, quoted on request) with professional research services including NCE discovery and optimization, new indication discovery (IndiSwitch), shelf compound re-evaluation (ReViva), and 360° Go/No-Go decision support (Prometheus/ChemDiagnostic). VLife serves pharmaceutical companies, academic and research institutions, biotech firms, and chemicals/materials industry customers — with named enterprise customers including Sun Pharma, Cipla, Mylan Labs, Unichem, Watson Pharma, Reliance Industries, HUL, and government accounts such as CDC Atlanta, alongside academic users including IISc, IIT Madras, NIPER, and National University of Singapore. Distribution is via direct enterprise licensing, academic institution agreements, and authorized reseller networks in Africa (Inqaba Biotechnical, SNBCHEMTECH) and Korea (Insilicogen).

Demand generation relies on industry conferences (ACS, BioExpo, CPhi India, EuroQSAR), academic training workshops at partner institutions, peer-reviewed publications, an annual Best Research Publication Award, and direct engagement with research institutions. The company holds DSIR R&D facility recognition (2008) and the BIRAC Innovator Award (2015). Operating status remains active with a headcount in the 11-50 range, though most recent customer-agreement news dates to 2015-2018, suggesting limited visible momentum or expansion since.

Name

VLife Sciences Technologies Pvt. Ltd.

Legal name

VLife Sciences Technologies Pvt. Ltd.

Website

https://vlifesciences.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

VLife Sciences Technologies, a Pune-based division of NovaLead Pharma, licenses computational drug discovery software (VLifeMDS, QSARpro, BioPredicta, ChemXplor) and provides research services to pharmaceutical companies, academic institutions, and chemicals/materials firms.

Ownership category

akta.pro rank

Product category

Computational Drug Discovery Software

NAICS

Scientific Research and Development Services (5417), Software Publishers (51321)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)

Keywords

• Computational drug discovery
• Molecular modeling software
• QSAR analysis tools
• Virtual screening software
• Computer-aided drug design

Headquarters

HQ city

Pune

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Software Licensing: VLifeMDS, QSARpro, BioPredicta, ChemXplor - comprehensive software suites for computer-aided drug design and QSAR analysis. Licensed to academic institutions, pharmaceutical companies, and research organizations on subscription or perpetual license basis.
2. Research Services: NCE discovery & optimization, New Indication discovery, Exploring shelf (Reviva), Go-no go decision support (ChemDiagnostic) - strategic research solutions for pharmaceutical pipeline enhancement.
3. Technology Services: Custom technology development, research automation, algorithm development, and database management services for specific client needs.
4. Training Services: Training programs, workshops, and hands-on sessions on computational drug design methods for academic and industry clients.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

VLife Sciences Technologies develops and licenses computational molecular discovery and drug design software suites (VLifeMDS, QSARpro, BioPredicta, ChemXplor) that combine molecular modeling, QSAR analysis, virtual screening, protein modeling, and ADME/Tox prediction capabilities. In addition to software licensing, the company delivers strategic research services including NCE discovery and optimization, new indication discovery (IndiSwitch), shelved compound re-evaluation (ReViva), and Go/No-Go decision support (Prometheus), along with custom technology development and training programs for pharmaceutical, biotech, academic, and chemical/materials organizations.

Product overview

VLife Sciences Technologies is a provider of licensed computational drug discovery software and research solutions. The product portfolio consists of four integrated product suites (VLifeMDS, QSARpro, BioPredicta, and ChemXplor) complemented by nine functional products (VLifeBase, VLife Engine, ProModel, VLifeDock, VLifeQSAR, MolSign, LeadGrow, ChemDBS, and ProViz). VLifeMDS serves as the flagship comprehensive molecular modeling suite, while QSARpro focuses on advanced QSAR analysis. The functional products provide specialized capabilities including protein modeling, molecular docking, database management, lead optimization, and visualization, which integrate within the main suites to deliver complete computer-aided drug design workflows.

Differentiator

Problem solved

Functional benefit

Products and services

• VLifeMDS Comprehensive molecular design and drug discovery software suite providing tools for computer-aided molecular design, QSAR, molecular modeling, virtual screening, and ADME/Tox predictions; licensed to pharmaceutical companies, biotech firms, and academic institutions worldwide.
• QSARpro Advanced quantitative structure-activity relationship analysis suite for new molecule design and lead optimization; targeted at medicinal chemists performing SAR studies.
• BioPredicta Bioinformatics product for predictive analysis in drug discovery applications, focused on biological property prediction.
• ChemXplor Cheminformatics product for chemical data analysis, exploration, and visualization supporting drug discovery workflows.
• Computational Research Services

Quantifiable outcome

• First multi-targeted NCE in India for Pancreatic cancer discovered exclusively with computational technologies - now in advanced animal trials
• +4 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core, major, flagship and minor.

• Sun PharmacoreStrategic or Co-development Partner · 1 October 2015Sun Pharma entered into agreement with VLife for computational drug discovery services. Relationship has been renewed multiple times (2017).
• Mylan Labs Ltd.coreStrategic or Co-development Partner · 1 January 2015Mylan Labs Hyderabad entered into agreement with VLife for research services.
• NovaLead Pharma Pvt. Ltd.coreStrategic or Co-development Partner · 1 October 2013VLife Sciences became a division of NovaLead Pharma Private Limited in October 2013, with VLife providing technology platform and NovaLead conducting drug discovery research.
• Unichem Laboratories Ltd.majorStrategic or Co-development Partner · 1 August 2013Unichem Laboratories entered into service agreement with VLife for drug discovery collaboration.
• Cipla Ltd.coreStrategic or Co-development Partner · 1 July 2013Cipla entered into service agreement with VLife for drug discovery collaboration. Multiple agreement renewals documented (2014, 2015, 2018).
• Watson PharmacoreStrategic or Co-development Partner · 1 February 2013Watson Pharma entered into agreement with VLife. Agreement renewed in 2014.
• Computational Research Laboratories (CRL), Tata GroupflagshipTechnology or Integration · 1 April 2010Strategic partnership to deliver high-speed virtual screening solutions combining VLife's computational drug design technology with CRL's high-performance computing capabilities.
• National Centre for Biological Sciences (NCBS), BengalurucoreStrategic or Co-development Partner · 1 March 2010VLife contracted to develop specialized modeling and simulation technology for protein-protein interactions. Project undertaken jointly by NCBS, Stanford University (USA), and Technical University of Denmark for cutting-edge computational molecular discovery research.
• Inqaba Biotechnical (Pty) Ltd.majorChannel Partner/ Reseller/ Distributor · 1 August 2009Appointed as authorized reseller for Africa, expanding VLife's geographic reach in the African market.
• Insilicogen, Inc.majorChannel Partner/ Reseller/ Distributor · 1 March 2009Appointed as authorized reseller for Republic of Korea, enabling market presence in Korea.
• SNBCHEMTECHminorChannel Partner/ Reseller/ Distributor · 1 September 2008Appointed as authorized reseller for Africa, expanding distribution network in African regions.
• Reliance Industries LimitedflagshipStrategic or Co-development Partner · 1 May 2008Research contract renewed for characterization and development of novel catalysts for olefin polymerization, focusing on ethylene oligomerization using Chromium catalysts.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Schrödinger, Inc. Schrödinger is the leading physics-based computational drug discovery platform with LiveDesign, FEP+ and a broad suite covering molecular modeling, docking, QSAR and ADME — directly overlapping VLifeMDS and QSARpro. It is a much larger publicly traded incumbent serving the same pharma, biotech and academic customer base.
• ACD/Labs (Advanced Chemistry Development): ACD/Labs offers cheminformatics and predictive ADME/Tox software (Percepta, Absolv, ACD/ChemSketch) used across pharma and chemistry R&D — adjacent to ChemXplor, ChemDBS and BioPredicta.
• Certara: Certara provides modeling and simulation software (e.g., ADMET Predictor, D360, Phoenix) used across pharma discovery, preclinical and clinical stages — adjacent to VLife's ADME/Tox and cheminformatics tools, with broader portfolio scale.
• Simulations Plus: Simulations Plus provides ADMET Predictor, GastroPlus and MonolixSuite for modeling pharmacokinetics, PBPK and quantitative systems pharmacology — comparable to VLife's ADME/Tox prediction modules and broader discovery-to-development footprint.
• Dassault Systèmes BIOVIA: BIOVIA offers Discovery Studio and a broad life-science software portfolio covering molecular modeling, QSAR, docking, ADME and biologics, competing head-to-head with VLife's suite across enterprise pharma and CRO customers.

Direct peers

• Optibrium: Optibrium's StarDrop platform combines QSAR, ADME prediction and lead optimization workflows with a strong European pharma and biotech user base — directly comparable to QSARpro and VLifeSCOPE.
• Chemical Computing Group (MOE): MOE (Molecular Operating Environment) is a long-standing integrated CADD platform for molecular modeling, QSAR and docking with deep adoption among academic and pharma medicinal chemists — overlapping directly with VLifeMDS.
• OpenEye Scientific (Cadence Design Systems): OpenEye provides molecular modeling, cheminformatics and ligand-based design software (e.g., OMEGA, FRED, ROCS) that directly competes with VLifeMDS, QSARpro and ChemXplor in pharma and academic discovery workflows.
• Cresset: Cresset provides ligand-based design (Flare, Spark) with field-based and electrostatic methods that overlap VLife's GQSAR and VLifeSCOPE capabilities, serving pharma and agrochemical discovery teams.

Emerging players

• InSilico Medicine: InSilico Medicine is an AI-native drug discovery company offering end-to-end target identification, generative chemistry and PandaOmics/Chemistry42 platforms — an emerging competitor in the same CADD/AI-for-drug-discovery category where VLife's QSAR and GQSAR compete.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vlife-sciences-technologies-pvt.-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VLife Sciences Technologies Pvt. Ltd.